Evidence map›Paper›PMID 41132345›Full record

ArticleTranslational andrology and urology2025

Lingdong Lv, Jing Wang, Lu Li

Abstract read
In one paragraph

Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lingdong LvDepartment of Urology, General Hospital of Ningxia Medical University, Yinchuan, China.
Jing WangDepartment of Pathology, General Hospital of Ningxia Medical University, Yinchuan, China.
Lu LiDepartment of Pathology, General Hospital of Ningxia Medical University, Yinchuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The gold standard treatment for non-muscle invasive bladder cancer (NMIBC) is transurethral resection of the bladder tumor (TURBT). Methods: Literature searches were conducted using PubMed, Embase, Cochrane Library, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), WanFang Data (WanFang) and VIP Information Network (VIP). We only included randomized controlled trials (RCTs). We used the Cochrane risk of bias 2.0 tool and modified Jadad scale to assess the quality of the literature. Statistical analyses were conducted using Review Manager 5.3 software (RevMan) and Stata SE software. Results: We included 16 RCTs comprising 1,505 patients (experimental group: 827; control group: 678). There were no significant differences between Conclusions: Compared with TURBT,

Indexed as

en bloc transurethral resectionNon-muscle invasive bladder cancer (NMIBC)transurethral resectiontransurethral resection of the bladder tumor (TURBT)

Identifiers

PMID41132345
PMCPMC12541490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.